Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.'s latest push into healthcare will disrupt Hims & Hers' business.

In an essay for 'Women's Health,' Dr. Nora Volkow discusses the future of semaglutide weight-loss meds, and their potential ...

Stryve Foods achieved continued revenue growth and improved gross margins, along with reduced operating expenses, in the ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief executive officer Michele Buck told analysts in a conference call on fiscal 2024 ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief ...

US equities overcame brief spells of volatility to reach new all-time highs in Q3 as underlying earnings growth remained positive. Read more here.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

A new joint study by the University of Eastern Finland and Karolinska Institutet in Sweden found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...